MedTrace Logo

Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT01059552 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-11-27

No results posted yet for this study

Summary

The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.

Conditions

  • Locally Advanced Non-small Cell Lung Cancer

Interventions

DRUG

vorinostat

vorinostat once daily for 12 weeks of therapy

Sponsors & Collaborators

Principal Investigators

  • Ranee Mehra, MD · Fox Chase Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-16
Primary Completion
2015-07-22
Completion
2019-10-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01059552 on ClinicalTrials.gov